Clinical Trial Update: A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus [Phase 2]

View source ↗

Summary

A Phase 2 open-label trial evaluating Lymphoseek (tilmanocept) for lymph node mapping in anal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer

Drugs mentioned

• Lymphoseek (tilmanocept)

Snippet

Sponsor: Cardinal Health 414, LLC | Conditions: Anal Cancer | Phase 2 | Status: WITHDRAWN